PURPOSE: The adenosine A(2A) receptor (A(2A)R) modulates normal vascularization and pathologic angiogenesis in many tissues and may contribute to the pathogenesis of retinopathy of prematurity (ROP) characterized by abnormal retinal vascularization in surviving premature infants. Here, the authors studied the effects of the genetic inactivation of A(2A)R on normal retinal vascularization and the development of pathologic angiogenesis in oxygen-induced retinopathy (OIR), an animal model of ROP. METHODS: After exposure to 75% oxygen for 5 days (postnatal day [P] 7-P12) and subsequently to room air for the next 9 days (P13-P21), we evaluated retinal vascular morphology by ADPase staining in retinal whole mounts, retinal neovascularization response by histochemistry in serial retinal sections, and retinal VEGF gene expression by real-time PCR analysis in A(2A)R knockout (KO) mice and their wild-type (WT) littermates. RESULTS: At P17, A(2A)R KO mice displayed attenuated OIR compared with WT littermates, as evidenced by reduced vaso-obliteration and areas of nonperfusion in the center of the retina, reduced pathologic angiogenesis as evident by decreased non-ganglion cells and neovascular nuclei, and inhibited hypoxia-induced retinal VEGF gene expression. Notably, the attenuation of pathologic angiogenesis by A(2A)R inactivation was selective for OIR because it did not affect normal retinal vascularization during postnatal development. CONCLUSIONS: These findings provide the first evidence that A(2A)R is critical for the development of OIR and suggest a novel therapeutic approach of A(2A)R inactivation for ROP by selectively targeting pathologic but not developmental angiogenesis in the retina.
PURPOSE: The adenosine A(2A) receptor (A(2A)R) modulates normal vascularization and pathologic angiogenesis in many tissues and may contribute to the pathogenesis of retinopathy of prematurity (ROP) characterized by abnormal retinal vascularization in surviving premature infants. Here, the authors studied the effects of the genetic inactivation of A(2A)R on normal retinal vascularization and the development of pathologic angiogenesis in oxygen-induced retinopathy (OIR), an animal model of ROP. METHODS: After exposure to 75% oxygen for 5 days (postnatal day [P] 7-P12) and subsequently to room air for the next 9 days (P13-P21), we evaluated retinal vascular morphology by ADPase staining in retinal whole mounts, retinal neovascularization response by histochemistry in serial retinal sections, and retinal VEGF gene expression by real-time PCR analysis in A(2A)R knockout (KO) mice and their wild-type (WT) littermates. RESULTS: At P17, A(2A)R KO mice displayed attenuated OIR compared with WT littermates, as evidenced by reduced vaso-obliteration and areas of nonperfusion in the center of the retina, reduced pathologic angiogenesis as evident by decreased non-ganglion cells and neovascular nuclei, and inhibited hypoxia-induced retinal VEGF gene expression. Notably, the attenuation of pathologic angiogenesis by A(2A)R inactivation was selective for OIR because it did not affect normal retinal vascularization during postnatal development. CONCLUSIONS: These findings provide the first evidence that A(2A)R is critical for the development of OIR and suggest a novel therapeutic approach of A(2A)R inactivation for ROP by selectively targeting pathologic but not developmental angiogenesis in the retina.
Authors: J F Chen; Z Huang; J Ma; J Zhu; R Moratalla; D Standaert; M A Moskowitz; J S Fink; M A Schwarzschild Journal: J Neurosci Date: 1999-11-01 Impact factor: 6.167
Authors: R P Mino; P E Spoerri; S Caballero; D Player; L Belardinelli; I Biaggioni; M B Grant Journal: Invest Ophthalmol Vis Sci Date: 2001-12 Impact factor: 4.799
Authors: M B Grant; M I Davis; S Caballero; I Feoktistov; I Biaggioni; L Belardinelli Journal: Invest Ophthalmol Vis Sci Date: 2001-08 Impact factor: 4.799
Authors: Yuan-Ji Day; Liping Huang; Marcia J McDuffie; Diane L Rosin; Hong Ye; Jiang-Fan Chen; Michael A Schwarzschild; J Stephen Fink; Joel Linden; Mark D Okusa Journal: J Clin Invest Date: 2003-09 Impact factor: 14.808
Authors: D Pereira-Figueiredo; R Brito; D S M Araújo; A A Nascimento; E S B Lyra; A M S S Cheibub; A D Pereira Netto; A L M Ventura; R Paes-de-Carvalho; K C Calaza Journal: Purinergic Signal Date: 2020-02-20 Impact factor: 3.765
Authors: R Brito; K C Calaza; D Pereira-Figueiredo; A A Nascimento; M C Cunha-Rodrigues Journal: Cell Mol Neurobiol Date: 2021-03-17 Impact factor: 5.046
Authors: Colin Niaudet; Jennifer J Hofmann; Maarja A Mäe; Bongnam Jung; Konstantin Gaengel; Michael Vanlandewijck; Elisabet Ekvärn; M Dolores Salvado; Annika Mehlem; Sahar Al Sayegh; Liqun He; Thibaud Lebouvier; Marco Castro-Freire; Kan Katayama; Kjell Hultenby; Christine Moessinger; Philip Tannenberg; Sara Cunha; Kristian Pietras; Bàrbara Laviña; JongWook Hong; Tove Berg; Christer Betsholtz Journal: PLoS One Date: 2015-09-22 Impact factor: 3.240